**Abstract**

Aggregation and deposition of amyloid-β peptide (Aβ) in the brain are triggering events of the long-term pathological cascade of Alzheimer's disease (AD), and are closely associated with the metabolic balance between Aβ anabolic and catabolic activities. As almost all familial AD mutations cause an increase in the anabolism of a particular form of Aβ, Aβ~1--42~, leading to Aβ deposition and accelerating AD pathology, a chronic reduction in the catabolic activity would also promote Aβ deposition. Neprilysin is a rate-limiting peptidase involved in brain Aβ catabolism. Mounting evidence that expression levels of neprilysin are decreased in the hippocampus and cerebral cortex of AD patients from the early stages of disease development and also with aging in humans, suggests a close association of neprilysin with the etiology and pathogenesis of AD. Thus, a subtle but long-term decline in neprilysin activity appears to be at least partly responsible for the memory-related symptoms of AD, and up-regulation of neprilysin would be a promising strategy for disease-modifying therapy of AD.

We screened a compound modulating brain neprilysin activity and/or gene expression using a natural product library, and found that catechins, such as EGCg were capable of up-regulating neprilysin via gene expression. However, their bioavailabilities and blood-brain barrier permeability are not always so good, because these compounds are highly hydrophilic. So, we synthesized aliphatic catechin derivatives by introducing an alkyl chain or aliphatic moiety into EGCg to increase Log P values. Interestingly, some of the aliphatic catechin derivatives more strongly up-regulated not only neprilysin but also α-secretase, which acts to preclude Aβ production, than EGCg did. The aliphatic catechins would be promising drug candidates for therapy and prevention of AD. Currently, we are analyzing their in vivo effects on up-regulation of neprilysin.
